首页> 外文OA文献 >Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

【2h】

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

机译：转移性去势抵抗性前列腺癌患者接受醋酸阿比特龙治疗4周后前列腺特异性抗原下降和总体生存率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Rescigno Pasquale; Lorente David; Bianchini Diletta; Ferraldeschi Roberta; Kolinsky Michael P.; Sideris Spyridon; Zafeiriou Zafeiris; Sumanasuriya Semini; Smith Alan D.; Mehra Niven; Jayaram Anuradha; Perez-Lopez Raquel; Mateo Joaquin; Parker Chris; Dearnaley David P.; Tunariu Nina; Reid Alison; Attard Gerhardt; de Bono Johann S.;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31 [J] . Conteduca Vincenza, Lolli Cristian, De Giorgi Ugo European urology . 2016,第6期

机译：回复：Pasquale Rescigno，David Lorente，Diletta Bianchini等。转移性去势抵抗性前列腺癌患者接受醋酸阿比特龙治疗4周后前列腺特异性抗原下降和总体生存率。 Eur Urol 2016; 70：724-31
2. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer [J] . Rescigno Pasquale, Lorente David, Bianchini Diletta, European urology . 2016,第5期

机译：转移性去势抵抗性前列腺癌患者接受醋酸阿比特龙治疗4周后前列腺特异性抗原下降和总体生存率
3. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31 [J] . Rescigno Pasquale, de Bono Johann S. European urology . 2016,第6期

机译：回复文森塔卡（Vincenza Conteduca），克里斯蒂安·洛里（Cristian Lolli）和乌戈·德·乔治（Ugo De Giorgi）写给编辑的信，回复者：帕斯夸莱·雷斯希尼奥（Pasquale Rescigno），大卫·洛伦特（David Lorente），狄莱塔·比安基尼（Diletta Bianchini）等。转移性去势抵抗性前列腺癌患者接受醋酸阿比特龙治疗4周后前列腺特异性抗原下降和总体生存率。 Eur Urol 2016; 70：724-31
4. Analysis of glycoforms of urinary prostate-specific antigen of prostate cancer and benign prostate hyperplasia samples [C] . Chun-Jen Hsiao, Tzong-Shin Tzai, Chein-Hung Chen, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：前列腺癌和良性前列腺增生样品的尿道前列腺特异性抗原糖族分析
5. Studies on human prostate-specific antigen as a tumor antigen for the immunotherapy of prostate cancer in a mouse model. [D] . Willis, Richard Allen. 2002

机译：人类前列腺特异性抗原作为一种肿瘤抗原的免疫模型在小鼠模型中的研究。
6. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [O] . Charles J. Ryan, E. David Crawford, Neal D. Shore, -1

机译：IMAAGEN研究：醋酸阿比特龙和泼尼松对非转移性去势抵抗性前列腺癌患者前列腺特异性抗原和放射学疾病进展的影响
7. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer [O] . Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, 2021

机译：使用AbiraTerone和苯甲丁酰胺的第一线治疗的四周的早期前列腺特异性抗原（PSA）变化可以预测转移性阉割抗性前列腺癌的早期/致力

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅